BLCAP is a highly conversed gene with two exons and an intron encoding a 10kDa protein, which was originally identified from invasive bladder carcinoma in 2002. BLCAP is subject to adenosine to inosine (A-to-I) RNA editing. A-to-I RNA editing is an important post-transcription modification of RNA sequence, generating a diversity of RNA products different from the original DNA sequence. The adenosine deaminase acting on double-stranded RNA (ADAR) family of enzymes catalyze the conversion of adenosine (A) to inosine (I) in the double stranded RNA, and inosine is finally recognized as guanosine (G) in the process of mRNA translation. May regulate cell proliferation and coordinate apoptosis and cell cycle progression via a novel mechanism independent of both p53/TP53 and NF-kappa-B.
Background References
1. Ben Safta T et al. Granzyme B-activated p53 interacts with Bcl-2 to promote cytotoxic lymphocyte-mediated apoptosis. J Immunol 194:418-28 (2015).
2. Sato J et al. Family with Sequence Similarity 5, Member C (FAM5C) Increases Leukocyte Adhesion Molecules in Vascular Endothelial Cells: Implication in Vascular Inflammation. PLoS One 9:e107236 (2014).
Sequence Similarity
Belongs to the BLCAP family.
Tissue Specificity
Ubiquitous. Expressed in cervical tissues. Down-regulated in bladder invasive carcinoma, renal cell carcinoma and in primary cervical carcinoma.
Western blot analysis of BLCAP on recombinant protein tissue lysate using anti-BLCAP antibody at 1/5,000 dilution.
ICC staining BLCAP (green) in HepG2 cells. The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Immunohistochemical analysis of paraffin-embedded human breast tissue using anti-BLCAP antibody. Counter stained with hematoxylin.
Immunohistochemical analysis of paraffin-embedded rat cervix tissue using anti-BLCAP antibody. Counter stained with hematoxylin.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"